Triple negative breast cancer

Looking for the missing link between biology and treatments

Giuseppe Palma, Giuseppe Frasci, Andrea Chirico, Emanuela Esposito, Claudio Siani, Carmela Saturnino, Claudio Arra, Gennaro Ciliberto, Antonio Giordano, Massimiliano D'Aiuto

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cancers. This acronym simply means that the tumour does not express oestrogen receptor (ER) and progesterone receptor (PR) and does not exhibit amplification of the human epidermal growth factor receptor 2 (HER2) gene. Despite this unambiguous definition, TNBCs are an heterogeneous group of tumours with just one common clinical feature: a distinctly aggressive nature with higher rates of relapse and shorter overall survival in the metastatic setting compared with other subtypes of breast cancer. Because of the absence of well-defined molecular targets, cytotoxic chemotherapy is currently the only treatment option for TNBC. In the last decades, the use of more aggressive chemotherapy has produced a clear improvement of the prognosis in women with TNBC, but this approach results in an unacceptable deterioration in the quality of life, also if some support therapies try to relieve patients from distress. In addition, there is the general belief that it is impossible to further improve the prognosis of TNBC patients with chemotherapy alone. In view of that, there is a feverish search for new "clever drugs" able both to rescue chemo-resistant, and to reduce the burden of chemotherapy in chemo-responsive TNBC patients. A major obstacle to identifying actionable targets in TNBC is the vast disease heterogeneity both inter-tumour and intra-tumour and years of study have failed to demonstrate a single unifying alteration that is targetable in TNBC. TNBC is considered the subtype that best benefits from the neoadjuvant model, since the strong correlation between pathological Complete Response and long-term Disease-Free-Survival in these patients. In this review, we discuss the recent discoveries that have furthered our understanding of TNBC, with a focus on the subtyping of TNBC. We also explore the implications of these discoveries for future treatments and highlight the need for a completely different type of clinical trials.

Original languageEnglish
Pages (from-to)26560-26574
Number of pages15
JournalOncotarget
Volume6
Issue number29
DOIs
Publication statusPublished - 2015

Fingerprint

Triple Negative Breast Neoplasms
Therapeutics
Drug Therapy
Neoplasms
Breast Neoplasms
erbB-1 Genes
Progesterone Receptors
Estrogen Receptors
Disease-Free Survival
Quality of Life
Clinical Trials

Keywords

  • Biology
  • Breast cancer
  • Oncology
  • Treatments
  • Triple negative

ASJC Scopus subject areas

  • Oncology

Cite this

Triple negative breast cancer : Looking for the missing link between biology and treatments. / Palma, Giuseppe; Frasci, Giuseppe; Chirico, Andrea; Esposito, Emanuela; Siani, Claudio; Saturnino, Carmela; Arra, Claudio; Ciliberto, Gennaro; Giordano, Antonio; D'Aiuto, Massimiliano.

In: Oncotarget, Vol. 6, No. 29, 2015, p. 26560-26574.

Research output: Contribution to journalArticle

@article{c09d5482502e44ebb0aa7107eae1143b,
title = "Triple negative breast cancer: Looking for the missing link between biology and treatments",
abstract = "The so called {"}Triple Negative Breast Cancer{"} (TNBC) represents approximately 15-20{\%} of breast cancers. This acronym simply means that the tumour does not express oestrogen receptor (ER) and progesterone receptor (PR) and does not exhibit amplification of the human epidermal growth factor receptor 2 (HER2) gene. Despite this unambiguous definition, TNBCs are an heterogeneous group of tumours with just one common clinical feature: a distinctly aggressive nature with higher rates of relapse and shorter overall survival in the metastatic setting compared with other subtypes of breast cancer. Because of the absence of well-defined molecular targets, cytotoxic chemotherapy is currently the only treatment option for TNBC. In the last decades, the use of more aggressive chemotherapy has produced a clear improvement of the prognosis in women with TNBC, but this approach results in an unacceptable deterioration in the quality of life, also if some support therapies try to relieve patients from distress. In addition, there is the general belief that it is impossible to further improve the prognosis of TNBC patients with chemotherapy alone. In view of that, there is a feverish search for new {"}clever drugs{"} able both to rescue chemo-resistant, and to reduce the burden of chemotherapy in chemo-responsive TNBC patients. A major obstacle to identifying actionable targets in TNBC is the vast disease heterogeneity both inter-tumour and intra-tumour and years of study have failed to demonstrate a single unifying alteration that is targetable in TNBC. TNBC is considered the subtype that best benefits from the neoadjuvant model, since the strong correlation between pathological Complete Response and long-term Disease-Free-Survival in these patients. In this review, we discuss the recent discoveries that have furthered our understanding of TNBC, with a focus on the subtyping of TNBC. We also explore the implications of these discoveries for future treatments and highlight the need for a completely different type of clinical trials.",
keywords = "Biology, Breast cancer, Oncology, Treatments, Triple negative",
author = "Giuseppe Palma and Giuseppe Frasci and Andrea Chirico and Emanuela Esposito and Claudio Siani and Carmela Saturnino and Claudio Arra and Gennaro Ciliberto and Antonio Giordano and Massimiliano D'Aiuto",
year = "2015",
doi = "10.18632/oncotarget.5306",
language = "English",
volume = "6",
pages = "26560--26574",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "29",

}

TY - JOUR

T1 - Triple negative breast cancer

T2 - Looking for the missing link between biology and treatments

AU - Palma, Giuseppe

AU - Frasci, Giuseppe

AU - Chirico, Andrea

AU - Esposito, Emanuela

AU - Siani, Claudio

AU - Saturnino, Carmela

AU - Arra, Claudio

AU - Ciliberto, Gennaro

AU - Giordano, Antonio

AU - D'Aiuto, Massimiliano

PY - 2015

Y1 - 2015

N2 - The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cancers. This acronym simply means that the tumour does not express oestrogen receptor (ER) and progesterone receptor (PR) and does not exhibit amplification of the human epidermal growth factor receptor 2 (HER2) gene. Despite this unambiguous definition, TNBCs are an heterogeneous group of tumours with just one common clinical feature: a distinctly aggressive nature with higher rates of relapse and shorter overall survival in the metastatic setting compared with other subtypes of breast cancer. Because of the absence of well-defined molecular targets, cytotoxic chemotherapy is currently the only treatment option for TNBC. In the last decades, the use of more aggressive chemotherapy has produced a clear improvement of the prognosis in women with TNBC, but this approach results in an unacceptable deterioration in the quality of life, also if some support therapies try to relieve patients from distress. In addition, there is the general belief that it is impossible to further improve the prognosis of TNBC patients with chemotherapy alone. In view of that, there is a feverish search for new "clever drugs" able both to rescue chemo-resistant, and to reduce the burden of chemotherapy in chemo-responsive TNBC patients. A major obstacle to identifying actionable targets in TNBC is the vast disease heterogeneity both inter-tumour and intra-tumour and years of study have failed to demonstrate a single unifying alteration that is targetable in TNBC. TNBC is considered the subtype that best benefits from the neoadjuvant model, since the strong correlation between pathological Complete Response and long-term Disease-Free-Survival in these patients. In this review, we discuss the recent discoveries that have furthered our understanding of TNBC, with a focus on the subtyping of TNBC. We also explore the implications of these discoveries for future treatments and highlight the need for a completely different type of clinical trials.

AB - The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cancers. This acronym simply means that the tumour does not express oestrogen receptor (ER) and progesterone receptor (PR) and does not exhibit amplification of the human epidermal growth factor receptor 2 (HER2) gene. Despite this unambiguous definition, TNBCs are an heterogeneous group of tumours with just one common clinical feature: a distinctly aggressive nature with higher rates of relapse and shorter overall survival in the metastatic setting compared with other subtypes of breast cancer. Because of the absence of well-defined molecular targets, cytotoxic chemotherapy is currently the only treatment option for TNBC. In the last decades, the use of more aggressive chemotherapy has produced a clear improvement of the prognosis in women with TNBC, but this approach results in an unacceptable deterioration in the quality of life, also if some support therapies try to relieve patients from distress. In addition, there is the general belief that it is impossible to further improve the prognosis of TNBC patients with chemotherapy alone. In view of that, there is a feverish search for new "clever drugs" able both to rescue chemo-resistant, and to reduce the burden of chemotherapy in chemo-responsive TNBC patients. A major obstacle to identifying actionable targets in TNBC is the vast disease heterogeneity both inter-tumour and intra-tumour and years of study have failed to demonstrate a single unifying alteration that is targetable in TNBC. TNBC is considered the subtype that best benefits from the neoadjuvant model, since the strong correlation between pathological Complete Response and long-term Disease-Free-Survival in these patients. In this review, we discuss the recent discoveries that have furthered our understanding of TNBC, with a focus on the subtyping of TNBC. We also explore the implications of these discoveries for future treatments and highlight the need for a completely different type of clinical trials.

KW - Biology

KW - Breast cancer

KW - Oncology

KW - Treatments

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=84944448623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944448623&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5306

DO - 10.18632/oncotarget.5306

M3 - Article

VL - 6

SP - 26560

EP - 26574

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -